To bring disruptive technologies in health, environment and sustainability, and biomanufacturing to market.
Most of our team has advanced training in science and our international Science Advisory Board is award-winning. We scout for ambitious SynBio projects and run pitch competitions to support the best in the field.
Spans many niche areas of SynBio research and commercialization across Europe. We nurture it through our Annual SynBio Day, pitch competitions, and participation to workshops and conferences.
We are 100% dedicated to investment in projects that use synthetic biology in the most innovative ways. We’re convinced that European research has immense potential to be exploited for the greater good.
Our investments span health, environment and bio-manufacturing. We support ventures at different stages of their development to maintain a balanced portfolio.
Synthetic biology applies techniques from engineering and computer sciences to biology. We believe it will revolutionize how we live, eat, and protect our planet.
of the materials we use could be made using biology
use cases with applications in healthcare, manufacturing, agriculture, energy and the environment
is the estimated value projection of direct economic impact of SynBio innovation by 2040
We act as a bridge between academia and industry, financing and developing synthetic biology innovation across Europe, UK, and Israel through an innovative investment model geared towards very early-stage start-ups and more mature SynBio companies.
We’re convinced that the right SynBio innovations will provide solutions to major challenges of our time.
Stay up to date with our latest news and events.
In collaboration with the European project SYNBEE, which strives to enhance entrepreneurship in synthetic biology across Europe, we are calling on researchers and entrepreneurs with disruptive synthetic biology solutions that address our planet's most pressing environmental and sustainability challenges.
While many big companies believe science is key to continue innovating and expanding (as is exemplified by substantial R&D budgets), I am convinced that SynBio tools have the potential to boost all areas of innovation.
The proposed transaction would represent the first cornerstone of eureKING’s project to pursue bolt-on acquisitions to add innovative companies from the fast growing biotherapies CDMO segment to its platform to create a bio-CDMO leader and which could result in additional transactions. These transactions may be announced before the completion of the proposed transaction.
eureKING has a clear and identified roadmap to bolster Skyepharma’s technology platform to consolidate the highly fragmented European market in biomanufacturing capacity, such as state-of-the-art facilities to manufacture cell and gene therapies in Europe.
The European project will enhance the commercial potential of one of today’s most disruptive fields
Ms. Lauvergeon brings an extensive background in the management of large energy corporations (most notably as CEO of Areva), finance, and government.
Luxembourg | France | Belgium
Subscribe to our news to keep in touch
